Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia

被引：5

作者：

Bacher, U ^{[1
]}

Kern, W ^{[1
]}

Schnittger, S ^{[1
]}

Hiddemann, W ^{[1
]}

Schoch, C ^{[1
]}

Haferlach, T ^{[1
]}

机构：

[1] Univ Munich, Lab Leukemia Diagnost, Klinikum Grosshadern, Dept Internal Med 3, D-81377 Munich, Germany

来源：

LEUKEMIA & LYMPHOMA | 2005年 / 46卷 / 03期

关键词：

CML; cytomorphology; cytogenetics; clonal evolution;

D O I：

10.1080/10428190400013068

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Staging of chronic myeloid leukemia (CML) phases is based on cytomorphological criteria that vary considerably between different staging systems. Thus, staging of CML is heterogeneous and causes problems with respect to the comparison of therapeutical strategies and clinical outcome. We evaluated 59 patients with CML in different stages of the disease. In order to de. ne which cytomorphological parameters correlate with cytogenetics we investigated cytomorphology and cytogenetics in parallel in all cases. As a result, bone marrow blast count demonstrated a highly significant correlation with the respective cytogenetic results of the patients and was clearly linked to the frequency and complexity of clonal evolution. We therefore propose to focus staging systems of CML on the correlation of the percentage of bone marrow blasts and the cytogenetic results.

引用

收藏

页码：357 / 366

页数：10

相关论文

共 26 条

[1] Identification of variant translocations in chronic myeloid leukemia by fluorescence in situ hybridization [J].

Acar, H ;

Stewart, J ;

Boyd, E ;

Conner, MJ .

CANCER GENETICS AND CYTOGENETICS, 1997, 93 (02) :115-118

[2] Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia [J].

Beck, Z ;

Kiss, A ;

Tóth, FD ;

Szabó, J ;

Bácsi, A ;

Balogh, E ;

Borbély, A ;

Telek, B ;

Kovács, E ;

Oláh, É ;

Rak, K .

LEUKEMIA & LYMPHOMA, 2000, 38 (5-6) :587-597

[3] Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial [J].

Buesche, G ;

Hehlmann, R ;

Hecker, H ;

Heimpel, H ;

Heinze, B ;

Schmeil, A ;

Pfirrmann, M ;

Gomez, G ;

Tobler, A ;

Herrmann, H ;

Kappler, M ;

Hasford, J ;

Buhr, T ;

Kreipe, HH ;

Georgii, A .

LEUKEMIA, 2003, 17 (12) :2444-2453

[4] Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy [J].

Cortes, JE ;

Talpaz, M ;

Giles, F ;

O'Brien, S ;

Rios, MB ;

Shan, J ;

Garcia-Manero, G ;

Faclerl, S ;

Thomas, DA ;

Wierda, W ;

Ferrajoli, A ;

Jeha, S ;

Kantarjian, HM .

BLOOD, 2003, 101 (10) :3794-3800

[5] Chronic myelogenous leukemia: Biology and therapy [J].

Faderl, S ;

Talpaz, M ;

Estrov, Z ;

Kantarjian, HM .

ANNALS OF INTERNAL MEDICINE, 1999, 131 (03) :207-219

[6] Mechanisms of disease - The biology of chronic myeloid leukemia [J].

Faderl, S ;

Talpaz, M ;

Estrov, Z ;

O'Brien, S ;

Kurzrock, R ;

Kantarjian, HM .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (03) :164-172

[7]

GANESAN TS, 1986, BLOOD, V68, P957

[8] Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment [J].

Goldman, JM ;

Melo, JV .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1451-1464

[9] Chronic myelogenous leukemia in blast crisis: Retrospective analysis of prognostic factors in 90 patients [J].

Griesshammer, M ;

Heinze, B ;

Hellmann, A ;

Popp, C ;

Anger, B ;

Heil, G ;

Bangerter, M ;

Heimpel, H .

ANNALS OF HEMATOLOGY, 1996, 73 (05) :225-230

[10] Karyotype abnormalities and their clinical significance in blast crisis of chronic myeloid leukemia [J].

Griesshammer, M ;

Heinze, B ;

Bangerter, M ;

Heimpel, H ;

Fliedner, TM .

JOURNAL OF MOLECULAR MEDICINE-JMM, 1997, 75 (11-12) :836-838